

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

SYNTHESIS OF SOME ACYCLONUCLEOSIDES α -(PYRAZOLO[3,4-d]PYRIMIDIN-4-YLTHIO)-ALKYLAMIDES

M. L. Taha; O. Moukha-Chafiq; H. B. Lazrek; J. J. Vasseur^a; J. L. Imbach^a

^a Université Montpellier II, Montpellier, France

Online publication date: 31 March 2001

To cite this Article Taha, M. L. , Moukha-Chafiq, O. , Lazrek, H. B. , Vasseur, J. J. and Imbach, J. L. (2001) 'SYNTHESIS OF SOME ACYCLONUCLEOSIDES α -(PYRAZOLO[3,4-d]PYRIMIDIN-4-YLTHIO)-ALKYLAMIDES', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 955 – 958

To link to this Article: DOI: 10.1081/NCN-100002467

URL: <http://dx.doi.org/10.1081/NCN-100002467>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF SOME ACYCLONUCLEOSIDES α -(PYRAZOLO[3,4-d]PYRIMIDIN-4-YLTHIO)- ALKYLAMIDES

M. L. Taha,¹ O. Moukha-Chafiq,¹ H. B. Lazrek,^{2,*}
J. J. Vasseur,³ and J. L. Imbach³

¹Lab. de Chimie Bio-Organique, Faculté des Sciences, Agadir, Morocco

²Lab. de Chimie Bio-Organique, Faculté des Sciences Semlalia,
Marrakech, Morocco

³Lab. de Chimie Organique Biomoléculaire de Synthèse, UMR 5625
CNRS-UM II, Université Montpellier II, Montpellier, France

ABSTRACT

The synthesis of some acyclic α -(pyrazolo[3,4-d]pyrimidin-4-ylthio)alkylamide nucleosides is described.

In the search for potent and selective chemotherapeutic agents, nucleosides and their derivatives are among the most widely explored types of compounds. The convenient general approach for their preparation involves the modification of the base and/or sugar residue of the nucleoside building blocks of deoxyribonucleic and ribonucleic acids (DNA and RNA respectively). Accordingly, the replacement of furanose ring by the appropriate pseudo-sugar moiety, e.g. (2-hydroxyethoxy)methyl, 4-hydroxybutyl or (2,3-dihydroxy-1-propoxy)methyl, is of particular interest since the resulting acyclovir (1) (ACV), HBG (2) or Iso-DHPG (3) (Fig. 1) have showed a potential anti-herpetic activity. In connection with our studies on acyclic nucleosides (4–6), we aimed through the synthesis of some acyclic α -(pyrazolo[3,4-d]pyrimidin-4-ylthio)alkylamide nucleosides (**14–16**)a-c (Fig. 1)

*Corresponding author.





Figure 1.

in order to determine the biological activities of the resulting base-modified derivatives of acyclovir, HBG and Iso-DHPG.

The 4-mercaptopyrazolo[3,4-d]pyrimidine **5**, depicted in scheme 1, was prepared in five steps according to the literature procedure from malononitrile and triethyl orthoformate as starting materials (7,8). The C4 sulfur atom of the base was alkylated with ethyl bromoacetate **6a**, (DL)-ethyl-2-bromopropionate **6b** or (DL)-ethyl-2-bromobutyrate **6c** in a sodium hydroxide solution at room temperature to give α -(pyrazolo[3,4-d]pyrimidin-4-ylthio)ethylalkylates **7a-c**, in 85%, 83% and 82% yield, respectively.


Then the preparation of compounds (**11-13**)a-c (Scheme 2) was achieved using the same conditions previously described for the synthesis of the 4-substituted pyrazolo[3,4-d]pyrimidine N₁-acyclonucleosides (4-6). Thus, the alkylation of heterocycles **7a**, **7b** or **7c** with alkylating agents **8** (9), **9** (6,10), or **10** (4), using potassium carbonate as base and N,N-dimethylformamide (DMF) as solvent, afforded regioselectively the N₁-regioisomers (**11-13**)a-c in 89%, 80% and 80%, respectively. It was reported that N₂-nucleoside (acyclonucleoside) formation occurred during glycosylation (alkylation) of the pyrazolo[3,4-d]pyrimidines (4,11-15). In our case presumed N₂-regioisomers of (**11-13**)a-c were detected but not isolated.

Finally, the treatment of N₁-protected acyclic nucleosides (**11-13**)a-c with methanol saturated with ammonia at room temperature gave the acyclic nucleosides (**14-16**)a-c (Scheme 2) in quantitative yield, through deprotection of the



Scheme 1.





Scheme 2.

acetyl group and concomitant conversion of the ester into the amide moiety. All structures of the synthetic products were identified by ¹H-NMR, mass spectra, UV and elemental analysis.

Compounds (14-16)a-c were evaluated for their cytotoxicity and their inhibitory effect on HIV-1(III_B) and HIV-2(ROD) replication in MT-4 cells (16,17). No significant activity was found against the replication of HIV-1(III_B) and HIV-2(ROD) at subtoxic concentrations.

In conclusion, we have regioselectively synthesized some N1-acyclic α-(pyrazolo[3,4-d]pyrimidin-4-ylthio)alkylamide nucleosides with the alkyl chain of acyclovir, HBG and Iso-DHPG. They were characterized on the basis of their physical and spectroscopic properties. Their anti-tumor and anti-tuberculosis evaluations are in progress.

ACKNOWLEDGMENTS

This work has been supported by «Recherches menées dans le cadre du Programme Thématique d'Appui à la Recherche Scientifique (PROTARS N° P1T2/02)». We thank Pr. E. De Clercq (Belgium) for the evaluation of the antiviral activity.

REFERENCES

- Schaeffer, H. J.; Beauchamp, L.; De miranda, P.; Elion, G. B.; Bauer, D. J.; Collins, P. *Nature*, **1978**, 272, 583-585.
- Larsson, A.; Alenius, S.; Johansson, N. G.; Öberg, B. *Antiviral Res.*, **1983**, 3, 77-86.
- Lin, T. S.; Liu, M. C. *Tetrahedron Lett.*, **1984**, 25, 905-906.
- Taha, M. L.; Lazrek, H. B. *Bull. Soc. Chim. Belg.*, **1997**, 106, 163-168.
- Taha, M. L.; Lazrek, H. B.; Barascut, J. L.; Imbach, J. L. *Bull. Soc. Chim. Belg.*, **1996**, 105, 279-285.



6. Taha, M. L.; Lazrek, H. B. *Bull. Soc. Chim. Belg.*, **1995**, *104*, 647–652.
7. Robins, R. K. *J. Am. Chem. Soc.*, **1956**, *78*, 784–790.
8. Huber, W., This Journal, **1943**, *65*, 2222–2226.
9. Robin, M. J.; Hatfield, P. W. *Can. J. Chem.*, **1982**, *60*, 547–553.
10. Lazrek, H. B.; Taourirte, M.; Barascut, J. L.; Imbach, J. L. *Bull. Soc. Chim. Belg.*, **1996**, *105*, 391–395.
11. Seela, F.; Zulauf, M.; Recher, G. *Nucleosides & Nucleotides*, **1997**, *16*, 305–314.
12. Seela, F.; Winter, H.; Moller, M. *Helv. Chim. Acta*, **1993**, *76*, 1450–1458.
13. Oertel, F.; Winter, H.; Kazimierczuk, Z.; Vilpo, J. A.; Richter, P.; Seela, F. *Liebigs. Ann. Chem.*, **1992**, 1165–1170.
14. Saxena, N. K.; Coleman, L. A.; Drach, J. C.; Townsend, J. C. *J. Med. Chem.*, **1990**, *33* (7), 1980–1983.
15. Kazimierczuk, Z.; Cottam, H. B.; Revankar, G. R.; Robins, R. K. *J. Am. Chem. Soc.*, **1984**, *106*, 6379–6382.
16. Pauwels, R.; Balzarini, J.; Baba, M.; Sneock, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. *J. Virol. Methods*, **1988**, *20*, 309–321.
17. Witvrouw, M.; Balzarini, J.; Pannecouque, C.; Jhaumar-Laullo, S.; Esté, J.; Schols, D.; Cherepanov, P.; Schmit, J.-C.; Debyser, Z.; Vandamme, A.-M.; Desmyter, J.; Ramadas, R.; De Clercq, E. *Antimicrob. Agents Chemother.*, **1997**, *41*, 262–268.



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002467>